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 The optimization of drug delivery system with approaches 
to a target in structure has been implicated to play a role in 
cancer chemotherapy, because it can reduce the adverse 
effects. However, this system partly reduces the direct 
cytotoxicity of anticancer drugs against tumor cells, in
comparison　 to　 its　free　 form.　 In　 the　 present　 study,　 poly(α-
malic acid) adriamycin (poly ADR) coated with saccharides 
including galactosamine which recognizes galactose-lectin 
specific to hepatocytes was prepared, and its cytotoxicities 
against Hep G2 cells (human hepatoblastoma), AZ521 cells 
(human gastric cancer) and KNS cells (human lung cancer) 
was evaluated using an in vitro cytotoxicity assay. In both 
AZ521 cells and KNS cells, poly ADR as well as poly ADR 
coated with glucosamine, glactosamine or mannosamine 
provided relatively lower cytotoxicities than the free form of 
ADR. In contrast, Hep G2 cells were to more efficiently 
sensitized, compared with the free form of ADR or poly ADR 
combined with or without glucosamine or mannosamine 
(P<0.01, respectively). These results indicate that poly ADR 
coated with galactosamine used as a cell recognition element 
is thus applicable for targeting cancer chemotherapy in the 
treatment of hepatocellular carcinoma.
Introduction 
 The drug delivery system contributes to an improved 
efficacy of cancer chemotherapy, because this system can 
reduce the Adverse effects (1-2). In addition, the utiliza-
tion of a cell-type-specific recognition elemental device is 
an ideal approach for targeting cancer chemotherapy. 
Many attempts have been made to develop successful 
methods of targeting cancer chemotherapy, and recent 
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studies have shown that saccharides function as a cell 
recognition motif in a variety of tumor cells (3-4). We 
previously reported that poly ( a -malic acid) adriamycin 
(poly ADR) appeared to offer some advantages in cancer 
chemotherapy (5). However, the tissue distribution of 
poly ADR, when injected, was not either cell or tissue-
specific in animal models. Galactose-specific asialogly-
coprotein receptor is localized selectively on the surface of 
hepatocytes and is recognized with poly (vinylbenzyl 
lactonamide) (PVLA) which has galactose residue in the 
tip. as described previously (6). In the present study, poly 
ADR was combined with such saccharides as glucosamine, 
galactosamine and mannosamine, and the cytotoxicities of 
these conjugates against Hep G2 cells (human hepato-
blastoma), AZ 521 cells (human gastric cancer) or KNS 
(human lung cancer) were thus investigated using an in 
vitro cytotoxicity assay.
Materials and Methods 
Chemicals 
 The structures of poly ADR or poly ADR combined with 
saccharides are shown in Fig. 1. These conjugates were 
synthesized according to the methods reported previously 
(5). ADR was obtained from Kyowa Hakko Kogyo Co. Ltd 
(Osaka, Japan). PVLA was a generous gift from Dr. A. 
Akimitsu, Kanagawa Academy of Science and Technology, 
Kanagawa, Japan. Na " I was purchased from the 
Amersham Co., (Tokyo, Japan). PVLA was radiolabeled 
with 'I by the iodogen method (7). 
Uptake of 9-labeled PVLA 
 Tumor cells (KNS : human lung cancer, AZ521 : human 
gastric cancer, Hep G2 : human hepatoblastoma) were 
placed on a 12-well plate (1.2x10'/ml) in 5%CO2 at 371C 
for 24 hours. The cells were reacted with "I labeled PVLA
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Fig. 1. Structure of poly (a -malic acid)/adriamycin/ 
             saccharide Molecular weight is about 1,500.
(lOkBq/ml) for 60 minutes. The cells were washed twice 
gently with PBS. The radioactivity of the cells was 
counted using a y -scintillation counter. The uptake of 
9-labeled PVLA was expressed according to the following 
formula : 
The uptake of 125I-labeled PVLA by the cell (%) = C/Co X 
100 
C : radioactivity of the cells measured 
Co : radioactivity of 1251-labeled PVLA administrated
Statistical analyses 
 Significant differences were assessed by a one way 
analysis of variance (ANOVA) or Fisher's PLSD Post-hoc 
test.
Results 
Uptake of 1251-labeled PVLA 
 The uptake of 125I-labeled PVLA by Hep G2 were signifi-
cantly higher than those by either KNS cells or AZ521 (Fig. 
2). It is likely that the galactose residue in the tip of PVLA 
recognizes the galactose-specific lectin on the cell surface 
of Hep G2 cells which are known to have asialoglyco-
protein receptors on the cell surface. 
Cytotoxic activity of conjugates 
 The direct cytotoxicities of poly ADR were lower than 
those of free form of ADR in all tumor cell lines used in 
this study (Fig. 3). Poly ADR combined with any of the 
saccharides did not enhance the cytotoxicities against 
either AZ521 cells or KNS cells. Similarly, combining poly 
ADR with glucosamine or mannosamine did not affect the 
cytotoxicities against Hep G2 cells, compared with poly 
ADR itself. However, when poly ADR was combined with 
galactosamine, the cytotoxicity of this conjugate against 
Hep G2 cells was significantly higher than poly ADR or 
even free form of ADR (P<0.01, respectively).
Cytotoxic activity of the conjugates 
 The in vitro cytotoxic activity of the conjugates against 
tumor cell lines (KNS, AZ521 and Hep G2) was determined 
by an MTT assay [3-(4,5-dimetylthiazol-2-yl)-2,5-dipheny-
ltetrazolium bromide] (9). Briefly, the tumor cell suspen-
sions (1 X 10'/ml) were placed on 96 well multi-plates and 
incubated either with the conjugates or free ADR (8,u g 
equivarent ADR per well) in 5 % CO2 at 371C. Thirty 
minutes later, the cells were washed twice with warmed 
RPMI 1640 media to remove the drugs, and incubated with 
fresh media without free ADR or the conjugates in 5% C 
02 at 37'C. One day later, the numbers of viable cells were 
determined: by means of MTT assay. The cytotoxic activity 
was calculated based on the following formula : Cytotoxic 
activity (%) = T/C X 100 
C : number of viable cells after 24h incubation without 
drug. 
T : number of viable cells after 24h incubation with drug.
Fig. 2. Uptake of 125I labeled PVLA 
The data are shown as the mean f S.D. 
 P<0.01 by a one way analysis of variance (ANOVA) 
and Fisher's PLSD Post-hoc test.
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Fig. 3. Cytotoxic activity of conjugates 
1 : free ADR, 2 : poly (a -malic acid)/ADR, 3 : poly (a -mal 
is acid)/glucosamine, 4 : poly ( a -malic acid)/mannosa-
mine, 5 : poly (a -malic acid) /gal actosamine 
The data are shown as the mean ± S.D. 
'P<0 .05, "'P<0.01 by a one way analysis of variance 
(ANOVA) and Fisher's PLSD Post-hoc test.
Discussion 
 The macromolecular anticancer drugs are not able to 
strengthen the direct cytotoxicities against tumor cells by 
itself, but they can reduce the adverse effects in compari-
son with the low molecular anticancer drug (8). ADR can 
be modified by poly ( a -malic acid), thus resulting in a 
macromolecular form poly ADR. In the present study, 
poly ADR was combined with saccharides (glucosamine, 
galactosamine, mannosamine) as a cell recognition ele-
mental device for targeting chemotherapy. Radiolabeled 
PVLA which has a galactose residue in the tip was selec-
tively incorporated into Hep G2 cells, but not in AZ521 
cells or KNS cells. Since previous studies showed that Hep 
G2 cells had galactose-lectin specific to hepatocytes on 
their cell surface, PVLA thus seems to be incorporated 
into Hep G2 cells through this cell surface receptor (9). By 
in vitro cytotoxicity assay, poly ADR combined with any 
of the saccharides did not enhance the cytotoxic activities 
against either AZ521 cells or KNS cells, but rather repre-
sented relatively lower cytotoxicities, compared with the 
free from of ADR. Similarly, poly ADR combined with 
glucosamine or mannosamine did not strengthen the 
tumoricidal activity against Hep G2 cells. In contrast, 
poly ADR combined with galactosamine resulted in a more 
pronounced growth inhibition of Hep G2 cells than the free 
form of ADR or other forms of poly ADR. These results 
thus suggest that galactosamine acts as a cell recognition 
motif and also enhances the incorporation of poly ADR 
into Hep G2 cells, thus leading to an efficient tumoricidal 
effect on Hep G2 cells. For targeting cancer chemotherapy, 
the drug delivery system is a key factor involved in the 
selective accumulation of anticancer drugs in tumor cells 
together with minimizing systemic adverse reaction. 
Recent advances in diagnostic techniques now allow us to 
detect hepatocellular carcinoma at an early stage. 
Nevertheless, however, there are few surgical candidates 
due to either widespread intrahepatic involvement or a 
lack of hepatic reserve due to the coexistence of advanced 
cirrhosis. Our above described approach is thus considered 
to be potentially effective as a cancer chemotherapy 
modality for the treatment of hepatocellular carcinoma.
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